Nkarta (NASDAQ:NKTX) Earns “Market Perform” Rating from William Blair

Nkarta (NASDAQ:NKTX)‘s stock had its “market perform” rating reaffirmed by research analysts at William Blair in a research note issued on Thursday, Marketbeat.com reports.

NKTX has been the subject of several other research reports. Needham & Company LLC lowered their price target on shares of Nkarta from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Thursday. HC Wainwright reiterated a “buy” rating and set a $18.00 price target on shares of Nkarta in a research report on Thursday, March 27th. Finally, Stifel Nicolaus decreased their price objective on shares of Nkarta from $15.00 to $14.00 and set a “buy” rating for the company in a report on Thursday, March 27th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Nkarta currently has an average rating of “Buy” and a consensus price target of $14.67.

Nkarta Price Performance

Shares of NASDAQ:NKTX opened at $1.74 on Thursday. Nkarta has a one year low of $1.31 and a one year high of $8.23. The company has a 50 day moving average of $1.79 and a 200-day moving average of $2.21. The stock has a market cap of $123.47 million, a price-to-earnings ratio of -0.93 and a beta of 0.81.

Nkarta (NASDAQ:NKTX) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.43) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.01. Equities research analysts anticipate that Nkarta will post -1.7 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of NKTX. Jefferies Financial Group Inc. grew its holdings in Nkarta by 901.7% during the fourth quarter. Jefferies Financial Group Inc. now owns 2,504,219 shares of the company’s stock valued at $6,236,000 after purchasing an additional 2,254,219 shares during the period. Tang Capital Management LLC lifted its stake in Nkarta by 252.9% in the fourth quarter. Tang Capital Management LLC now owns 2,293,719 shares of the company’s stock valued at $5,711,000 after buying an additional 1,643,719 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Nkarta by 138.7% in the fourth quarter. JPMorgan Chase & Co. now owns 2,537,922 shares of the company’s stock valued at $6,319,000 after buying an additional 1,474,560 shares in the last quarter. Monaco Asset Management SAM bought a new position in Nkarta in the first quarter valued at approximately $1,496,000. Finally, Alyeska Investment Group L.P. lifted its stake in Nkarta by 54.7% in the first quarter. Alyeska Investment Group L.P. now owns 2,064,956 shares of the company’s stock valued at $3,800,000 after buying an additional 730,260 shares in the last quarter. Institutional investors and hedge funds own 80.54% of the company’s stock.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.